ta observations, page-14

HI Tradie.

I should say upfront that I've been a bit of a contrarian when it comes to some of the (what I see) as overly optimistic views about NEU, but that said..... the company has got some good preclin data and has suggested the drugs it has may be useful in a wide range of contexts. Hence, there's been a deal of enthusiasm about a very large number of prospective target groups for its treatments. Bear in mind though that the actual number of drug candidates is far lower (NNZ-2256 is by far the dominant candidate) and that if it fails in early trials, it will obviously dampen enthusiasm for the prospects in other settings. of course, success in one will raise hopes it will work in others too.

The company is also relatively well funded - for example, the US Army is sponsoring its investigations of its lead drug as a possible treatment for traumatic brain injury in the hope it will be a useful treatment for battlefield injuries, so the trial is not likely to fall over due to lack of funding.

Have a look at the analysts reports by all means and search for an early post by Supertramp some time back (I think 2012?) which also laid out a good case for it being undervalued and it has probably gone up about 5-fold since then. Matter of conjecture as to whether that is justified or sustainable without positive clinical trial results, but the company has good PR (including a bunch of one-eyed folk o this forum) so that is helping to maintain enthusiam in the absence of more concrete clinical evidence. Hope that overview helps.